A real-time impedance-based screening assay for drug-induced vascular leakage

Toxicological Sciences

Volumn 138, Issue 2, 2014, Pages 333-343

  Kustermann, Stefan ^a   Manigold, Tobias ^a,b   Ploix, Corinne ^a   Skubatz, Marion ^a   Heckel, Tobias ^a   Hinton, Heather ^a   Weiser, Thomas ^a   Singer, Thomas ^a   Suter, Laura ^a,c   Roth, Adrian ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Barrier function; Drug development; HUVEC; Mab

Indexed keywords

INTERLEUKIN 1BETA; THROMBIN; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD VESSEL PERMEABILITY; CELL LINE; COST EFFECTIVENESS ANALYSIS; DRUG INDUCED DISEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR DISEASE; VASCULAR LEAKAGE;

BARRIER FUNCTION; DRUG DEVELOPMENT; HUVEC; MAB;

CAPILLARY PERMEABILITY; DRUGS, INVESTIGATIONAL; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; TIME FACTORS; TOXICITY TESTS;

EID: 84896455205     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft336     Document Type: Article

References (26)

1. Aghajanian, A., Wittchen, E. S., Allingham, M. J., Garrett, T. A., and Burridge, K. (2008). Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. J. Thromb. Haemost. 6, 1453-1460.
2. Baluna, R.G. (2007). Cytokine-induced vascular leak syndrome. In Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications (Methods in Pharmacology and Toxicology) (R. V. House and J. Descotes, Eds.), pp. 205-231, Humana Press Inc., Totowa, NJ.
3. Baumer, Y., Burger, S., Curry, F. E., Golenhofen, N., Drenckhahn, D., and Waschke, J. (2008). Differential role of Rho GTPases in endothelial barrier regulation dependent on endothelial cell origin. Histochem. Cell Biol. 129, 179-191.
4. Baumer, Y., Funk, D., and Schlosshauer, B. (2010). Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells? Cell. Mol. Life Sci. 67, 2451-2465.
5. Bazzoni, G. (2006). Endothelial tight junctions: Permeable barriers of the vessel wall. Thromb. Haemost. 95, 36-42.
6. Buk, D. M., Renner, O., and Graeve, L. (2005). Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80. Eur. J. Cell Biol. 84, 819-831.
7. Capaldo, C. T.,, and Nusrat, A. (2009). Cytokine regulation of tight junctions. Biochim. Biophys. Acta 1788, 864-871.
8. Cohen, S. B., Woolley, J.M., and Chan, W. (2003). Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 30, 225-231.
9. Desai, T. R., Leeper, N. J., Hynes, K. L., and Gewertz, B. L. (2002). Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J. Surg. Res. 104, 118-123.
10. Dewi, B. E., Takasaki, T., and Kurane, I. (2004). In vitro assessment of human endothelial cell permeability: Effects of inflammatory cytokines and dengue virus infection. J. Virol. Methods 121, 171-180.
11. Dudek, S. M.,, and Garcia, J. G. (2001). Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487-1500.
12. Elias, J. A., Jimenez, S. A., and Freundlich, B. (1987). Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am. Rev. Respir. Dis. 135, 62-65.
13. Furuse,M., Sasaki, H., Fujimoto, K., and Tsukita, S. (1998).Asingle gene product, claudin-1 or-2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 143, 391-401.
14. Kovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R.T., Jr, Falloon, J., Polis,M. A., Walker, R. E., Stevens, R., and Salzman, N. P. (1995). Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567-575.
15. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. (1986). Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-2772.
16. Ludwig, A., Sommer, A., and Uhlig, S. (2011). Assessment of endothelial permeability and leukocyte transmigration in human endothelial cell monolayers. Methods Mol. Biol. 763, 319-332.
17. Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., Macfarlane, J. D., Antoni,C., Leeb,B., Elliott, M. J., and Woody, J. N. (1998). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563.
18. Makri, O. E., Georgalas, I., and Georgakopoulos, C. D. (2013). Drug-induced macular edema. Drugs 73, 789-802.
19. Oshima, T., Laroux, F. S., Coe, L. L., Morise, Z., Kawachi, S., Bauer, P., Grisham, M. B., Specian, R. D., Carter, P., and Jennings, S. (2001). Interferongamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc. Res. 61, 130-143.
20. Peck, A.W., Fowle, A. S., and Bye, C. (1975). A comparison of triprolidine and clemastine on histamine antagonism and performance tests in man: Implications for the mechanism of drug induced drowsiness. Eur. J. Clin. Pharmacol. 8, 455-463.
21. Puhlmann, M., Weinreich, D. M., Farma, J. M., Carroll, N. M., Turner, E. M., and Alexander, H. R., Jr, (2005). Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J. Transl. Med. 3, 37. doi: 10.1186/1479-5876-3-37.
22. Rabiet, M. J., Plantier, J. L., Rival, Y., Genoux, Y., Lampugnani, M. G., and Dejana, E. (1996). Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler. Thromb. Vasc. Biol. 16, 488-496.
23. Seybold, J., Thomas, D., Witzenrath, M., Boral, S., Hocke, A. C., Burger, A., Hatzelmann, A., Tenor, H., Schudt, C., and Krull, M. (2005). Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: Role in endothelial hyperpermeability. Blood 105, 3569-3576.
24. Siegel, J. P.,, and Puri, R. K. (1991). Interleukin-2 toxicity. J. Clin. Oncol. 9, 694-704.
25. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
26. Vandenbroucke, E., Mehta, D., Minshall, R., and Malik, A. B. (2008). Regulation of endothelial junctional permeability. Ann. N. Y. Acad. Sci. 1123, 134-145.